Thus, the complete loss of ER/PR expression underscores the dynamic heterogeneity and adaptive potential of the tumor, with significant implications for subsequent therapeutic decisions, necessitating a shift from endocrine therapy toward alternative strategies such as anti-HER2 agents. This evidence concerns the gene ERBB2 and neoplasm.